
Turn Therapeutics Inc.: updates and filings
Price
$8.10
November 20, 2026Market cap $241M
What Ploutos Investor adds for Turn Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 2 fiscal years, from 2024
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
November 2026
August 2026
May 2026
March 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026FilingFormEFFECT
- Nov 16, 2026FilingFormEFFECT
- Nov 10, 2026Regulation FD disclosureForm8-K
- Nov 9, 2026Shelf registration for future offeringsFormS-3
- Nov 9, 2026Shelf registration for future offeringsFormS-3
- Nov 9, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 9, 2026Results of operationsForm8-K
- Oct 19, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Oct 19, 2026Annual meeting proxy statementFormDEF 14A
- Oct 7, 2026Regulation FD disclosureForm8-K
- Sep 10, 2026Regulation FD disclosureForm8-K
- Sep 9, 2026Regulation FD disclosureForm8-K
- Aug 26, 2026FilingFormD
- Aug 18, 2026Unregistered sale of sharesForm8-K
- Aug 17, 2026Regulation FD disclosureForm8-K
- Aug 12, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 12, 2026Results of operationsForm8-K
- Jul 28, 2026Regulation FD disclosureForm8-K
- Jul 7, 2026Regulation FD disclosureForm8-K
- Jun 3, 2026Regulation FD disclosureForm8-K
- Jun 1, 2026Regulation FD disclosureForm8-K
- May 27, 2026Regulation FD disclosureForm8-K
- May 19, 2026Regulation FD disclosureForm8-K
- May 18, 2026Regulation FD disclosureForm8-K
- May 13, 2026FilingFormC-TR
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | EFFECT | Filing | Document |
| Nov 16, 2026 | EFFECT | Filing | Document |
| Nov 10, 2026 | 8-K | Regulation FD disclosure | Document |
| Nov 9, 2026 | S-3 | Shelf registration for future offerings | Document |
| Nov 9, 2026 | S-3 | Shelf registration for future offerings | Document |
| Nov 9, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 9, 2026 | 8-K | Results of operations | Document |
| Oct 19, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Oct 19, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Oct 7, 2026 | 8-K | Regulation FD disclosure | Document |
| Sep 10, 2026 | 8-K | Regulation FD disclosure | Document |
| Sep 9, 2026 | 8-K | Regulation FD disclosure | Document |
| Aug 26, 2026 | D | Filing | Document |
| Aug 18, 2026 | 8-K | Unregistered sale of shares | Document |
| Aug 17, 2026 | 8-K | Regulation FD disclosure | Document |
| Aug 12, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 12, 2026 | 8-K | Results of operations | Document |
| Jul 28, 2026 | 8-K | Regulation FD disclosure | Document |
| Jul 7, 2026 | 8-K | Regulation FD disclosure | Document |
| Jun 3, 2026 | 8-K | Regulation FD disclosure | Document |
| Jun 1, 2026 | 8-K | Regulation FD disclosure | Document |
| May 27, 2026 | 8-K | Regulation FD disclosure | Document |
| May 19, 2026 | 8-K | Regulation FD disclosure | Document |
| May 18, 2026 | 8-K | Regulation FD disclosure | Document |
| May 13, 2026 | C-TR | Filing | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since May 22, 2024.
The full analysis
What do Turn Therapeutics's filings show?
The filings are where every one of Turn Therapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.